| Document |
Document Title |
|
WO/2023/155158A1 |
A use of a composition in preparation of a medicament for promoting wound healing in diabetes is provided, wherein the composition comprises an effective amount of mangosteen fruit shell extract.
|
|
WO/2023/156745A1 |
The present invention relates to a cosmetic or dermatological composition comprising a myrtle extract and a Tripterygium wilfordii extract, in particular with at least one cosmetically acceptable or dermatologically acceptable excipient,...
|
|
WO/2023/158281A1 |
The present invention relates to a metal thiooctoyl hyaluronate complex and a composition comprising same, the complex consisting of alpha-lipoic acid, metal, and hyaluronic acid. The metal thiooctoyl hyaluronate complex of the present i...
|
|
WO/2023/155837A1 |
PHARMACEUTICAL COMPOSITION HAVING ANALGESIC AND/OR ANTIPRURITIC FUNCTIONS AND USE THEREOF The composition contains a Nav1.7 inhibitor and a Nav1.8 inhibitor, and the weight ratio of the Nav1.7 inhibitor to the Nav1.8 inhibitor is 1:(0.00...
|
|
WO/2023/158242A1 |
Provided are a polypeptide having hair loss treating or hair growth promoting activity and use thereof.
|
|
WO/2023/155880A1 |
A method for regulating membrane repair and/or a membrane repair related biological process is provided, comprising regulating the amount and/or function of TSPAN4, which can help cells mitigate damage caused by laser, detergent, pyropto...
|
|
WO/2023/156588A1 |
The present invention relates to the cosmetic use of at least one dirhamnolipid of general formula (I): and also the salts thereof, solvates thereof and optical isomers thereof, for reducing and/or inhibiting the development of the colou...
|
|
WO/2023/156864A1 |
Provided is an inhibitor of AXL, Mer, and/or c-Met of Formula (I) or a pharmaceutically acceptable salt thereof: Formula (I), in which R1, R2, R3, G, and Q are described herein. Further provided is a method of treating or preventing an A...
|
|
WO/2023/158051A1 |
The present invention relates to: a peptide exhibiting an anti-inflammatory function; a fused compound comprising same; and drugs, cosmetics, foods, medical devices, etc. comprising same. The present inventors discovered that a peptide o...
|
|
WO/2023/155756A1 |
Disclosed in the present invention is the use of a lipoic acid nanoparticle in the preparation of a drug for treating diseases related to oxidative stress, which belongs to the technical field of biomedicine. The drug for treating diseas...
|
|
WO/2023/158164A1 |
The present invention relates to a composition for promoting collagen production, comprising an amidated amino acid and, more specifically, to a composition which, by promoting collagen production in various cells such as fibroblasts, ha...
|
|
WO/2023/158286A1 |
The present invention pertains to a calsequestrin-based metal ion reactive particle and uses thereof. More specifically, the present invention pertains to: a calsequestrin-based metal ion reactive particle prepared by binding a physiolog...
|
|
WO/2023/155879A1 |
Provided are methods and compositions for regulating an immune cell relating functions, by regulating the formation and/or function of a migrasome generated by another immune cell.
|
|
WO/2023/159123A1 |
The current disclosure provides compositions and methods for treating and/or debriding damaged or dying tissue resulting from a range of injuries and conditions without requiring surgical personnel or facilities. The compositions can be ...
|
|
WO/2023/158092A1 |
Provided are a pharmaceutical composition for hemostasis in the gastrointestinal tract and a pharmaceutical composition for wound healing in the gastrointestinal tract. The pharmaceutical compositions, according to one embodiment, may co...
|
|
WO/2023/154953A1 |
The present disclosure provides methods of treating and preventing autoimmune disorders (e.g., multiple sclerosis (MS)), said methods comprising administering to a subject (e.g., a human) in need thereof a therapeutically effective amoun...
|
|
WO/2023/152727A1 |
Dermatological composition comprising: - water present in a concentration by weight, evaluated with respect to the total weight of the composition, greater than 30%; - at least one hydrolyzed extract of silk proteins present in a concent...
|
|
WO/2023/153861A1 |
The present invention relates to a pharmaceutical composition comprising curcumin and ginsenoside, and a formulation comprising same. Using curcumin and ginsenoids according to the present invention in combination with butyric acid and s...
|
|
WO/2023/153776A1 |
The composition containing deglycosylated recombinant keratin as an active ingredient has hair growth promotion and hair regeneration effects superior to those of glycosylated human hair keratin, and thus can be used for preventing and t...
|
|
WO/2023/152241A1 |
The invention relates to an agent from the group of anion exchangers, preferably colestyramine, for the care and prophylaxis of wounds and injuries, in particular in the presence of local bacterial infections or critical colonizations, w...
|
|
WO/2023/154014A1 |
The usage of NMDAR antagonists provides compositions and methods for treatment for the malfunctioning of the protein homeostasis network and interferes with crucial signaling pathways and is often associated with multiple human diseases....
|
|
WO/2023/154479A1 |
The present disclosure relates to a formulations and methods for transdermal delivery of a medicament through the skin of a subject. In aspects, the formulation comprises a therapeutically effective amount of a medicament and a penetrant...
|
|
WO/2023/151898A1 |
The invention relates to compounds of general formula (I).
|
|
WO/2023/151897A1 |
The invention relates to compounds of general formula (I).
|
|
WO/2023/152748A1 |
The present invention relates to skin care preparations comprising callus-derived pluripotent cells of a plant of the genus Cannabis, including Cannabis saliva I.,, and Cannabis indica, compositions comprising same and use thereof for pr...
|
|
WO/2023/153479A1 |
A cell population which contains 75% or more of CD11b positive, F4/80 positive, CD180 positive and CD9 positive macrophages derived from a tissue selected from the group consisting of placenta, umbilical cord and amnion, and which contai...
|
|
WO/2023/152656A2 |
Formulations containing biologically-produced, high-purity R-mevalonolactone are provided for modulating the expression of genes and metabolism related to epidermal turnover, hyaluronic acid synthesis, barrier function, anti-aging elasti...
|
|
WO/2023/150376A1 |
Provided herein are methods and compositions related to Prevotella histicola bacteria for the reduction of IL-23, LL-12b, and IL-17 levels in a subject.
|
|
WO/2023/149227A1 |
[Problem] To provide a skin care composition that effectively inhibits elastase activity. [Solution] A skin care composition comprising (A) a cyclic carboxamide derivative having a specific structure or a salt of the derivative, and (B) ...
|
|
WO/2023/148501A1 |
The present invention relates to compounds of formula (I) that are MALT1 inhibitors. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to p...
|
|
WO/2023/149226A1 |
[Problem] To provide a skin care composition that effectively inhibits tyrosinase activity. [Solution] A skin care composition comprising (A) a cyclic carboxamide derivative having a specific structure or a salt of the derivative, and (B...
|
|
WO/2023/150694A1 |
The present disclosure provides compositions comprising two or more natural preservatives, wherein the natural preservatives are rosmarinic acid, dihydroquercetin, kaempferol, caffeic acid, apigenin, ferulic acid, p-coumaric acid, orcino...
|
|
WO/2023/149692A1 |
The present invention relates to a method for preparing a copper-containing in situ hydrogel and use thereof, the method using a polymer into which a phenol group or a compound including a phenol group has been introduced, a copper compo...
|
|
WO/2023/150241A1 |
Disclosed herein are methods for the treatment or prevention of topical or oral microbiome dysfunction in a subject in need thereof. The methods comprise the step of administering to the subject a compound capable of signaling the reduct...
|
|
WO/2023/149408A1 |
The present invention provides a cosmetic composition, a cosmetic composition for epidermal keratinocyte proliferation, an epidermal keratinocyte proliferation agent, an antioxidant, a cosmetic composition for dermal papilla cell prolife...
|
|
WO/2023/149639A1 |
The purpose of the present invention is to provide a composition for preventing hair loss or promoting hair growth, the composition comprising a Persicaria pubescens extract as an active ingredient. The present invention was derived on t...
|
|
WO/2023/149225A1 |
[Problem] To provide a skin care composition that effectively inhibits tyrosinase activity and elastase activity. [Solution] A skin care composition comprising (A) a cyclic carboxamide derivative having a specific structure or a salt of ...
|
|
WO/2023/148428A1 |
According to an example aspect of the present invention, there is provided non-therapeutic use of an effective amount of substances derived from Nordic plants, such as birch sap, fermented oat extract, extracts or dried powders derived f...
|
|
WO/2023/148248A1 |
Disclosed is a monoclonal IgG antibody designated as 2G4 which - is specific for the membrane-proximal extracellular region EC5 of Desmoglein-3 designated as human Dsg3-EC5 (aa451-566) - shows no cross-reaction with mouse Dsg3 or human D...
|
|
WO/2023/150149A1 |
The present invention provides modified sophorolipids of formula (I) incorporating therapeutic molecules as therapeutic agent cargos to improve the bioavailability and/or delivery of such agents. The modified sophorolipids of the present...
|
|
WO/2023/145959A1 |
A medicine for treating or preventing interstitial lung disease and the disease or symptoms associated with systemic scleroderma in a subject, said medicine containing, as an active ingredient, 1-\{2-[(3S,4R)-1-\{[(3R,4R)-1-cyclopentyl-3...
|
|
WO/2023/143184A1 |
Among others, the invention provides a topical composition for preventing or treating skin aging, comprising at least one compound selected from the group consisting of ergothioneine, an analog or derivative thereof, or a dermatologicall...
|
|
WO/2023/144699A1 |
The disclosure relates to an anti-IL-23p19 antibody hum13B8-b or antigen binding fragment thereof and its use in the treatment of plaque psoriasis of the scalp.
|
|
WO/2023/145619A1 |
This non-enveloped virus inactivation composition comprises: (a) a positive ion surfactant; (b) at least one selected from (b1) aliphatic alcohols having a cLogP of 0.80-2.40 and (b2) aromatic alcohols having a cLogP of 1.4-2.0; and water.
|
|
WO/2023/142996A1 |
A method for preventing, alleviating and/or treating a disease or disorder associated with administering an antineoplastic agent. The method comprises administering to a subject in need thereof a NO-NSAID compound or a pharmaceutically a...
|
|
WO/2023/146490A1 |
The present invention discloses a wound dressing (8) and the production method thereof that is made of a polymer selected from the group of polyvinyl alcohol (PVA), polylactic (PLA) polylactic (PLA), polyglycolic acid (PGA), poly lactic-...
|
|
WO/2023/143394A1 |
The present invention relates to an injection containing stable macromolecular I-type recombinant collagen. The collagen injection contains macromolecular I-type recombinant collagen, injection water and excipients, wherein the macromole...
|
|
WO/2023/146426A1 |
The present invention relates to fluvoxamine for use in the treatment of psoriasis as a topical formulation.
|
|
WO/2023/144118A1 |
METHODS OF THERAPY COMPRISING SIMULTANEOUS ADMINISTRATION OF METHOTREXATE AND FOLIC ACID 5 Methotrexate (MTX) is an antineoplastic agent used the treatment of a wide variety of diseases including cancers and inflammatory autoimmune disea...
|
|
WO/2023/143345A1 |
A pharmaceutical composition comprises the following raw materials in percentage by weight: 0.6 to 2.9% of tofacitinib tartrate; 5 to 30% of diethylene glycol monoethyl ether; 5 to 20% of an emulsifier; and 31.1 to 77.4% of purified wate...
|
